Sanofi has had a busy year on the deal-making front in 2021 and is ending the year by once again jumping on the M&A merry-go-round to bolster its vaccines pipeline and buy Austria's Origimm Biotechnology.
Privately owned Origimm specializes in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease. Its...








